NACvsNoopept

NAC is deacetylated to cysteine, the rate-limiting substrate for glutathione synthesis via gamma-glutamylcysteine synthetase and glutathione synthetase. Glutathione (GSH) is the primary intracellular antioxidant in neurons, neutralizing reactive oxygen species and maintaining redox balance. NAC also activates the cystine-glutamate antiporter (System Xc-, composed of SLC7A11 and SLC3A2 subunits), which exchanges extracellular cystine for intracellular glutamate in a 1:1 ratio. This non-vesicular mechanism modulates extrasynaptic glutamate levels, reducing NMDA receptor overactivation and excitotoxicity. The glutamate-modulating effect explains NAC's promise in OCD (reducing corticostriatal glutamate hyperactivity), addiction (normalizing nucleus accumbens glutamate after drug exposure), and neurodegenerative conditions involving glutamate dysregulation.

Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.